734 related articles for article (PubMed ID: 11159857)
1. Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen.
Bentrem D; Dardes R; Liu H; MacGregor-Schafer J; Zapf J; Jordan V
Endocrinology; 2001 Feb; 142(2):838-46. PubMed ID: 11159857
[TBL] [Abstract][Full Text] [Related]
2. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351.
MacGregor Schafer J; Liu H; Bentrem DJ; Zapf JW; Jordan VC
Cancer Res; 2000 Sep; 60(18):5097-105. PubMed ID: 11016635
[TBL] [Abstract][Full Text] [Related]
3. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
Dardes RC; O'Regan RM; Gajdos C; Robinson SP; Bentrem D; De Los Reyes A; Jordan VC
Clin Cancer Res; 2002 Jun; 8(6):1995-2001. PubMed ID: 12060645
[TBL] [Abstract][Full Text] [Related]
4. Resveratrol acts as an estrogen receptor (ER) agonist in breast cancer cells stably transfected with ER alpha.
Levenson AS; Gehm BD; Pearce ST; Horiguchi J; Simons LA; Ward JE; Jameson JL; Jordan VC
Int J Cancer; 2003 May; 104(5):587-96. PubMed ID: 12594813
[TBL] [Abstract][Full Text] [Related]
5. Control of the estrogen-like actions of the tamoxifen-estrogen receptor complex by the surface amino acid at position 351.
Levenson AS; MacGregor Schafer JI; Bentrem DJ; Pease KM; Jordan VC
J Steroid Biochem Mol Biol; 2001; 76(1-5):61-70. PubMed ID: 11384864
[TBL] [Abstract][Full Text] [Related]
6. Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor alpha complex.
Liu H; Lee ES; Deb Los Reyes A; Zapf JW; Jordan VC
Cancer Res; 2001 May; 61(9):3632-9. PubMed ID: 11325832
[TBL] [Abstract][Full Text] [Related]
7. Regulation of estrogen target genes and growth by selective estrogen-receptor modulators in endometrial cancer cells.
Dardes RC; Schafer JM; Pearce ST; Osipo C; Chen B; Jordan VC
Gynecol Oncol; 2002 Jun; 85(3):498-506. PubMed ID: 12051881
[TBL] [Abstract][Full Text] [Related]
8. Characterization of molecular and structural determinants of selective estrogen receptor downregulators.
Fan M; Rickert EL; Chen L; Aftab SA; Nephew KP; Weatherman RV
Breast Cancer Res Treat; 2007 May; 103(1):37-44. PubMed ID: 17033922
[TBL] [Abstract][Full Text] [Related]
9. Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells.
Liu H; Park WC; Bentrem DJ; McKian KP; Reyes Ade L; Loweth JA; Schafer JM; Zapf JW; Jordan VC
J Biol Chem; 2002 Mar; 277(11):9189-98. PubMed ID: 11751902
[TBL] [Abstract][Full Text] [Related]
10. Estrogen receptor alpha mediated induction of the transforming growth factor alpha gene by estradiol and 4-hydroxytamoxifen in MDA-MB-231 breast cancer cells.
MacGregor Schafer J; Liu H; Levenson AS; Horiguchi J; Chen Z; Jordan VC
J Steroid Biochem Mol Biol; 2001 Jul; 78(1):41-50. PubMed ID: 11530283
[TBL] [Abstract][Full Text] [Related]
11. A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats.
Greenberger LM; Annable T; Collins KI; Komm BS; Lyttle CR; Miller CP; Satyaswaroop PG; Zhang Y; Frost P
Clin Cancer Res; 2001 Oct; 7(10):3166-77. PubMed ID: 11595711
[TBL] [Abstract][Full Text] [Related]
12. Functional implications of antiestrogen induction of quinone reductase: inhibition of estrogen-induced deoxyribonucleic acid damage.
Bianco NR; Perry G; Smith MA; Templeton DJ; Montano MM
Mol Endocrinol; 2003 Jul; 17(7):1344-55. PubMed ID: 12714703
[TBL] [Abstract][Full Text] [Related]
13. The interaction of raloxifene and the active metabolite of the antiestrogen EM-800 (SC 5705) with the human estrogen receptor.
Schafer JI; Liu H; Tonetti DA; Jordan VC
Cancer Res; 1999 Sep; 59(17):4308-13. PubMed ID: 10485477
[TBL] [Abstract][Full Text] [Related]
14. Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone.
Willson TM; Norris JD; Wagner BL; Asplin I; Baer P; Brown HR; Jones SA; Henke B; Sauls H; Wolfe S; Morris DC; McDonnell DP
Endocrinology; 1997 Sep; 138(9):3901-11. PubMed ID: 9275080
[TBL] [Abstract][Full Text] [Related]
15. Comparative analyses of mechanistic differences among antiestrogens.
Wijayaratne AL; Nagel SC; Paige LA; Christensen DJ; Norris JD; Fowlkes DM; McDonnell DP
Endocrinology; 1999 Dec; 140(12):5828-40. PubMed ID: 10579349
[TBL] [Abstract][Full Text] [Related]
16. Basic guide to the mechanisms of antiestrogen action.
MacGregor JI; Jordan VC
Pharmacol Rev; 1998 Jun; 50(2):151-96. PubMed ID: 9647865
[TBL] [Abstract][Full Text] [Related]
17. Modulation of estrogen receptor alpha function and stability by tamoxifen and a critical amino acid (Asp-538) in helix 12.
Pearce ST; Liu H; Jordan VC
J Biol Chem; 2003 Feb; 278(9):7630-8. PubMed ID: 12496244
[TBL] [Abstract][Full Text] [Related]
18. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines.
Pink JJ; Jordan VC
Cancer Res; 1996 May; 56(10):2321-30. PubMed ID: 8625307
[TBL] [Abstract][Full Text] [Related]
19. The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor.
Levenson AS; Jordan VC
Cancer Res; 1998 May; 58(9):1872-5. PubMed ID: 9581827
[TBL] [Abstract][Full Text] [Related]
20. Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor.
Connor CE; Norris JD; Broadwater G; Willson TM; Gottardis MM; Dewhirst MW; McDonnell DP
Cancer Res; 2001 Apr; 61(7):2917-22. PubMed ID: 11306468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
